Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Hepatic Cysts

NCT02048319 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Symptomatic Dominant Liver Cyst

Interventions

DRUG: Pasireotide LAR 60 mg
PROCEDURE: Aspiration sclerotherapy
DRUG: Placebo

Sponsor

Radboud University Medical Center